All terms

Series A / B / C Financing Rounds

Sequential priced equity rounds in venture-backed companies, typically progressing from product-market validation (A) to scale (B) to growth (C+).

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

Series A, B, C, and later rounds are sequential priced equity financings in venture-backed companies. Each Series corresponds to a new class of preferred stock with its own price, liquidation preference, and protective provisions. Series A typically funds product-market validation (in MedTech: feasibility study, IDE planning, early IP), Series B funds pivotal trial execution and regulatory clearance, and Series C+ funds commercial launch and scale. MedTech rounds tend to be larger and longer-spaced than software rounds because of trial timelines and capital intensity.

What this means in practice

MedTech-specific dynamics: round timing usually maps to regulatory milestones (IDE, first-in-human, pivotal completion, FDA submission, FDA clearance, first revenue). Strategic investors (Medtronic, J&J, Boston Scientific corporate venture arms) often participate in B/C rounds and may negotiate ROFR or future M&A optionality.

Common pitfalls

•Raising too little at Series A and being forced into a down round when a trial enrollment slips.
•Optimizing for valuation over investor quality — strong leads pay dividends in later rounds.

Primary references

3 sources

Link health: 3 verified· last checked 2026-05-09

NVCA·1SEC·1SVB·1

Inline markers like [1] jump to the matching reference above.

On this term

Category: Investment & Finance
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Sequential priced equity rounds in venture-backed companies, typically progressing from product-market validation (A) to scale (B) to growth (C+).

·MedTech-specific dynamics: round timing usually maps to regulatory milestones (IDE, first-in-human, pivotal completion, FDA submission, FDA clearance, first revenue).
·Strategic investors (Medtronic, J&J, Boston Scientific corporate venture arms) often participate in B/C rounds and may negotiate ROFR or future M&A optionality.
·Each Series corresponds to a new class of preferred stock with its own price, liquidation preference, and protective provisions.

Remember this

Watch out: Raising too little at Series A and being forced into a down round when a trial enrollment slips.

Related terms

You may also need

Auto-suggested from Investment & Finance and shared keywords.

All Investment & Finance terms